A reagent deal may be priced as one commercial package, but it is rarely one regulatory object.

The offer can combine analysers, assay kits, calibrators, controls, consumables, middleware, LIS integration, preventive maintenance, spare parts, training and a multi-year supply commitment. Treating the analyser’s authorisation as a shortcut for the entire package creates a risk that appears only after award—when a catalogue code cannot be supplied, an assay is outside the verified scope, or the cost model omitted controls and wastage.

Start with the bill of offer

Build a controlled bill of offer before final pricing. Each tender line should map to:

  • manufacturer and catalogue number;
  • product type and intended purpose;
  • applicable regulatory status;
  • selling and tender unit;
  • pack size and shelf life;
  • compatible analyser or software version;
  • forecast demand and replenishment owner;
  • installation, maintenance and response obligations.

This is not clerical work. It connects the regulatory identity to the commercial promise.

One package, three tests

**Regulatory test.** Can every device, IVD, accessory and software element be traced to the appropriate regulatory scope? An MDMA for the main analyser should not be assumed to cover every reagent, control or software function in the bid. SFDA grouping guidance applies defined criteria; commercial bundling is not regulatory bundling.

**Economic test.** What does one reportable result actually consume? A kit label may state a nominal number of tests, but calibration, controls, dead volume, repeats, start-up and expiry can change the delivered economics. The bid model should show the assumptions rather than hide them in an average.

**Operational test.** Can the supplier meet the promise over the contract term? Check lead time, cold-chain conditions where relevant, buffer stock, engineer coverage, spare parts, software support and escalation. A complete regulatory file cannot compensate for a service model that cannot be executed.

Run a single-assay simulation

Choose one assay and follow it from forecast to reported patient result. Identify its reagent, calibrator, control, analyser, software version, storage condition and service dependency. Then simulate a delayed shipment, a lot problem and an analyser outage.

The exercise should answer:

  • Which approved code can be supplied?
  • Who authorises a substitute?
  • How is the customer informed?
  • Does the substitute change performance, validation or contract terms?
  • What is the cost of continuity?
  • Which record shows that the delivered item matches the bid?

If one assay cannot pass the simulation, a large menu will not become manageable after award.

Four owners, one approval gate

Regulatory signs the product-identity matrix. Commercial signs price assumptions and exclusions. Supply signs forecast, shelf-life and continuity. Service signs installation, integration, maintenance and response capacity.

The bid is approved only when all four are looking at the same version. The resulting crosswalk should remain controlled from tender submission through purchase order, invoice, delivery and complaint handling.

Version control matters after approval as much as before it. If a catalogue code, software release, pack configuration or service assumption changes, the crosswalk should return to the owners affected by that change. Record the effective date, customer impact and disposition of open purchase orders. Otherwise, the approved tender file becomes a historical snapshot while sales and supply execute a different package.

What Basier can and cannot do

“Reagent Deal” describes a procurement model, not an SFDA regulatory category. Basier can review the consistency of the regulatory, commercial and operating package, build the catalogue crosswalk and make assumptions visible before bid approval. Basier does not guarantee award, approve substitutions on behalf of the buyer or SFDA, or replace legal review of tender and contract terms.

Official sources

Turn the requirements into a clear plan for your case

Start with an assessment of the device and available evidence before deciding on submission.

Basier Regulatory Services